Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Free Cash Flow (2023 - 2025)

Historic Free Cash Flow for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to -$19.8 million.

  • Artiva Biotherapeutics' Free Cash Flow fell 6913.81% to -$19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.9 million, marking a year-over-year decrease of 5095.37%. This contributed to the annual value of -$55.7 million for FY2024, which is 983.66% down from last year.
  • Artiva Biotherapeutics' Free Cash Flow amounted to -$19.8 million in Q3 2025, which was down 6913.81% from -$23.7 million recorded in Q2 2025.
  • Artiva Biotherapeutics' Free Cash Flow's 5-year high stood at -$10.9 million during Q3 2023, with a 5-year trough of -$23.7 million in Q2 2025.
  • In the last 3 years, Artiva Biotherapeutics' Free Cash Flow had a median value of -$14.7 million in 2024 and averaged -$15.8 million.
  • In the last 5 years, Artiva Biotherapeutics' Free Cash Flow tumbled by 713.83% in 2024 and then crashed by 6913.81% in 2025.
  • Over the past 3 years, Artiva Biotherapeutics' Free Cash Flow (Quarter) stood at -$11.3 million in 2023, then tumbled by 30.09% to -$14.7 million in 2024, then plummeted by 34.57% to -$19.8 million in 2025.
  • Its Free Cash Flow stands at -$19.8 million for Q3 2025, versus -$23.7 million for Q2 2025 and -$20.7 million for Q1 2025.